Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 76,004
  • Shares Outstanding, K 42,940
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,450 K
  • 36-Month Beta 3.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.87

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.53 +16.34%
on 02/01/18
2.07 -13.93%
on 01/24/18
-0.28 (-13.59%)
since 01/23/18
3-Month
1.53 +16.34%
on 02/01/18
2.32 -23.28%
on 11/30/17
-0.42 (-19.09%)
since 11/22/17
52-Week
0.88 +102.27%
on 08/23/17
2.95 -39.66%
on 11/13/17
+0.36 (+25.35%)
since 02/23/17

Most Recent Stories

More News
This Morning's Technical Outlook on Biotech Stocks -- NewLink Genetics, OHR Pharma, Omeros, and OncoSec Medical

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on NLNK, OHRP, OMER, and ONCS which can be accessed for free by signing up to www.wallstequities.com/registration....

OHRP : 0.25 (unch)
ONCS : 1.78 (+0.56%)
OMER : 10.00 (+11.11%)
NLNK : 7.10 (+1.43%)
OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a biotechnology company focused on designing, developing and commercializing innovative immunotherapies and proprietary medical approaches to stimulate...

ONCS : 1.78 (+0.56%)
OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock

OncoSec Medical Incorporated (NASDAQ: ONCS), a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide...

ONCS : 1.78 (+0.56%)
OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced preliminary clinical observations related to its pilot...

ONCS : 1.78 (+0.56%)
OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment of Gregory T. Mayes to its board of directors....

ONCS : 1.78 (+0.56%)
OncoSec Provides 2018 Business Outlook

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, announced its anticipated operational milestones for 2018 and a review...

ONCS : 1.78 (+0.56%)
OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the initiation of patient dosing in PISCES/KEYNOTE-695,...

ONCS : 1.78 (+0.56%)
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer....

ONCS : 1.78 (+0.56%)
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has added two patents to its broad patent portfolio....

ONCS : 1.78 (+0.56%)
OncoSec Receives $9.3 Million Warrant Exercise

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it has entered into entered into a Warrant Exercise Agreement...

ONCS : 1.78 (+0.56%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

2nd Resistance Point 1.86
1st Resistance Point 1.82
Last Price 1.78
1st Support Level 1.75
2nd Support Level 1.72

See More

52-Week High 2.95
Fibonacci 61.8% 2.16
Fibonacci 50% 1.91
Last Price 1.78
Fibonacci 38.2% 1.67
52-Week Low 0.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.